GW Pharmaceutical (GWPH: NASDAQ) has quietly outperformed most of its fellow NASDAQ companies during 2015 and Technical420 has been recommending them the whole time. GWPH is up over 10% today and over 36% this year. The company manufactures and sells the first prescribed cannabis-based medicine in over 20 countries and its deep product pipeline will lead to incremental revenue growth for years to come.
A pharmaceutical, not marijuana, company
Many people think that GW Pharmaceutical is a marijuana company, but they are not. GWPH is a pharmaceutical company focused on developing treatments derived from cannabis. The company has an extensive product pipeline with each product in various stages of FDA testing. The company’s two main products in focus are Sativex and Epidolex.
Their Sativex product for cancer pain is in late stage 3 testing and they expect to receive data in the near future. If the drug is approved by the FDA, GWPH will enter a high demand market where they have no competition.
Epidolex is also a major needle move for GWPH. These treatments offer nearly 250,000 people in the United States and Europe an alternative treatment for intractable epilepsy. Current treatments on the market today are known to have horrible side effects. The latest trials have shown that Epidiolex does not cause any side effects aside of fatigue, which will allow GWPH to dominate the market.
Additional Pipeline products
GWPH has an additional epilepsy pipeline candidate GWP42006 (Cannabidivarin or CBDV). This product has competed phase 1 testing and enters phase 2a trials during the first half of 2015
Phase 1b/2a trials of GWP42002 and GWP42003 for the treatment of Glioma is advancing to second phase.
Top line data from Phase 2a trial of GWP42003 (extract) for the treatment of ulcerative colitis has shown signals of efficacy in patients who received the treatment
Phase 2a trial of GWP42003 for the treatment of schizophrenia commenced in March 2014. They expect to complete testing during the second half of 2015.
- Phase 2b trial of GWP42004 in type-2 diabetes commenced in March 2014 and is expected to be completed during 2016.
Entering new markets in 2015
GW Pharmaceutical sells their Sativex product throughout Europe, but the company has its sights set on entering the United States market during 2015.
The FDA granted the fast track designation to GWPH‘s investigational cannabidiol product, Epidiolex, for the treatment of Dravet syndrome. GWPH expects to complete most of the Epidiolex development program during 2015, as well as start to build a U.S. commercial presence in anticipation of the future launch.
GWPH is progressing towards the conclusion of U.S. Phase 3 cancer pain trials for Sativex, the world’s first plant-derived cannabinoid prescription drug. GWPH expects to report data from the trials in early 2015 which, if positive, would enable the filing of New Drug Application (NDA) with the FDA in the second half of 2015.
GWPH has been outperforming the market this year, but the company still trades at a discount to the average Wall Street price target. Technical420 attributes this rally to the company being added to the International Equity Portfolio at Bank of America/Merrill Lynch. A 2% allocation was added to the portfolio as of the close of trading March 12, 2015. Technical420 is favorable on GWPH and we think that the bipartisan bill submitted by three Senators could be a major catalyst for the stock. If this bill is approved, cannabis will become a Schedule II substance and CBD medicines will be allowed to be sold between states. These two provisions represent huge catalysts shares for GWPH.
WANT TO KNOW MORE???
If you want more great information like this, or if want investing advice, register for a Pro Trader membership at https://technical420.com/user/register. You will not be charged during the first week and you can cancel anytime FOR FREE!
Technical420 LLC is not a FINRA member firm. Technical420 LLC is responsible for the preparation and distribution of research created in the United States. Technical420 LLC is located at 40 SW 13th St. Suite 1002, Miami, FL 33130.
Technical 420 LLC, and any of its directors, officers, employees, affiliates, or subsidiaries does not accept any form of compensation from companies in return for writing reports on them. Also Technical 420 LLC, and any of its directors, officers, employees, affiliates, or subsidiaries do not hold any stock positions in companies covered by Technical420LLC.